We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

This study is currently recruiting participants.
Verified March 2017 by Aleksandar Videnovic, MD, Northwestern University
Sponsor:
ClinicalTrials.gov Identifier:
NCT01742182
First Posted: December 5, 2012
Last Update Posted: March 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
National Institute of Neurological Disorders and Stroke (NINDS)
Information provided by (Responsible Party):
Aleksandar Videnovic, MD, Northwestern University
  Purpose
Disruption of sleep and alertness is one of the most disabling non-motor symptoms of Parkinson's disease (PD). Mechanisms leading to impaired sleep and alertness in PD are not well understood, and treatment options remain limited. The proposed research will examine markers of the circadian system, sleepiness and sleep quality in PD patients and healthy controls. Further, the project will examine effects of bright light exposure on circadin function, sleep and alertness in PD.

Condition Intervention
Parkinson's Disease Other: Light exposure

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Circadian Rhythms and Sleep-Wake Cycles in Parkinson's Disease

Resource links provided by NLM:


Further study details as provided by Aleksandar Videnovic, MD, Northwestern University:

Primary Outcome Measures:
  • circadian rhythm of melatonin [ Time Frame: June 2012- May 2017 ]
  • Sleep Efficiency [ Time Frame: June 2012- May 2017 ]
  • Daytime Somnolence [ Time Frame: June 2012- May 2017 ]

Estimated Enrollment: 80
Study Start Date: June 2012
Estimated Study Completion Date: June 2017
Estimated Primary Completion Date: June 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: Control
No Intervention: PD patients without sleep problems
Active Comparator: PD patients with sleep problems
light exposure
Other: Light exposure
Placebo Comparator: PD patients with sleep problem
light exposure
Other: Light exposure

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   55 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Diagnosis of idiopathic PD as defined by the United Kingdom PD Society Brain Bank Criteria;
  2. PD Hoehn and Yahr stage 2-4;
  3. Pittsburgh Sleep Quality Index (PSQI) score >5 in group 1, and ≤5 in group 2;
  4. Epworth Sleepiness Scale (ESS) score ≥10 in group 1, and <10 in group 2;

Control participants will be matched for gender and age with PD participants.

Exclusion Criteria:

  1. Atypical or secondary forms of Parkinsonism;
  2. Cognitive impairment as determined by the Mini-Mental State Examination (MMSE) score of ≤ 26;
  3. Presence of depression defined as the Beck Depression Inventory (BDI) score >14;
  4. Use of hypno-sedative drugs for sleep or stimulants; participants will be allowed to taper these drugs and will become eligible at least 4 weeks after the taper is completed;
  5. Use of SSRIs / SNRIs antidepressants, unless the participant has been on a stable dose for at least 3 months prior to the screening;
  6. Use of medications known to affect melatonin secretion;
  7. Unstable/serious medical illness.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01742182


Contacts
Contact: Laura Wulf, MA 312-503-1999 l-wulf@northwestern.edu
Contact: Karen Williams, BA 312-503-5645 k-williams8@northwestern.edu

Locations
United States, Illinois
Northwestern University Recruiting
Chicago, Illinois, United States, 60611
Principal Investigator: Aleksandar Videnovic, MD         
Sponsors and Collaborators
Massachusetts General Hospital
National Institute of Neurological Disorders and Stroke (NINDS)
Investigators
Principal Investigator: Aleksandar Videnovic, MD Northwestern University
  More Information

Responsible Party: Aleksandar Videnovic, MD, Assistant Professor of Neurology, Northwestern University
ClinicalTrials.gov Identifier: NCT01742182     History of Changes
Other Study ID Numbers: Circadian Rhythms in PD
1K23NS072283-01A1 ( U.S. NIH Grant/Contract )
First Submitted: December 3, 2012
First Posted: December 5, 2012
Last Update Posted: March 24, 2017
Last Verified: March 2017

Keywords provided by Aleksandar Videnovic, MD, Northwestern University:
Parkinson's Disease
Excessive Daytime Sleepiness
Circadian Rhythms
Light Therapy

Additional relevant MeSH terms:
Parkinson Disease
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases